inhibiitide

Inhibiitide is a short peptide consisting of 20 amino acids that was first identified in the bark of an African medicinal plant. The peptide was isolated in 1998 by a research team at the University of Pretoria using reversed‑phase high‑performance liquid chromatography followed by mass spectrometry. Its sequence (KVRNQGILTNFLPRVHAGD) features a high proportion of hydrophobic residues and includes a conserved proline at position nine, which is thought to confer resistance to proteolytic degradation.

Inhibiitide functions as a selective inhibitor of serine proteases, with highest potency against trypsin and chymotrypsin. In vitro assays indicate that the peptide binds reversibly to the enzyme’s active‑site pocket, disrupting substrate access and producing mixed‑type inhibition kinetics. The peptide also displays antimicrobial properties against Gram‑positive bacteria, potentially by permeabilizing cellular membranes.

Several studies have examined inhibiitide’s therapeutic potential. A synthetic analogue lacking the N‑terminal lysine retained inhibitory activity while improving pharmacokinetics. Research on plant defense mechanisms suggested that the peptide is upregulated during pathogen attack and may contribute to innate immune responses. Despite encouraging in‑vitro data, large‑scale production, in‑vivo efficacy, and the safety profile of inhibiitide in mammalian systems remain to be fully elucidated. Continued investigation into its biochemical properties and potential medical applications is ongoing.